AR054988A1 - 4-amino-piridopirimidinonas sustituidas, un procedimiento para preparar los compuestos y medicamento en base a aquellos - Google Patents
4-amino-piridopirimidinonas sustituidas, un procedimiento para preparar los compuestos y medicamento en base a aquellosInfo
- Publication number
- AR054988A1 AR054988A1 ARP050104688A ARP050104688A AR054988A1 AR 054988 A1 AR054988 A1 AR 054988A1 AR P050104688 A ARP050104688 A AR P050104688A AR P050104688 A ARP050104688 A AR P050104688A AR 054988 A1 AR054988 A1 AR 054988A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkylene
- mono
- het
- hal
- nr3r4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la formula (1), en donde: R1 es Ar o Het1; R2 es A, Hal, OH, OA o CN; R3, R4 son en cada caso, de modo independiente entre sí, H o A; X es fenileno no sustituido o mono-, di-, tri- o tetrasustituido con R2; o un heterociclo aromático de 6 miembros con 1-2 átomos de N, que no está sustituido o que puede estar mono-, di-, tri- o tetrasustituido con R2; Ar es un carbociclo aromático mono- o bicíclico C6-10, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, alquenilo C2-6, alquinilo C2-6, NO2, NH2, NHA, NA2, COOHM, COOA, CN, Het, -O-Het, -O-alquilen-Het, -O-alquilen-NR3R4, -NR3-alquilen-NR3R4, CONR3R4, y/u -O-alquilen- NR3-alquilen-OR3; Het1 es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O, y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, OH, alquenilo C2-6, alquinilo C2-6, NO2, NH, NHA, NA2, COOH, COOA, CN, -O-Het, -O- alquilen-Het, -O-alquilen-NR3R4, -NR3-alquilen-NR3R4, CONR3R4 y/u -O-alquilen-NR3-alquilen-OR3; Het es un heterociclo mono- o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O, y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, OA, CN, y/o el oxígeno del carbonilo (=O); A es alquilo C1-10, en donde también 1-7 átomos de H pueden estar reemplazados por F y/o cloro; Hal es F, Cl, Br, o I; así como sus derivados, solvatos, sales, tautomeros y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de las tirosina quinasas, en especial de la TIE-2, y de las Raf-quinasas, y pueden utilizarse, por ejemplo, para el tratamiento de tumores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004054216A DE102004054216A1 (de) | 2004-11-10 | 2004-11-10 | Substituierte 4-Amino-pyridopyrimidinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054988A1 true AR054988A1 (es) | 2007-08-01 |
Family
ID=35759422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104688A AR054988A1 (es) | 2004-11-10 | 2005-11-09 | 4-amino-piridopirimidinonas sustituidas, un procedimiento para preparar los compuestos y medicamento en base a aquellos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7846927B2 (es) |
| EP (1) | EP1809629B1 (es) |
| JP (1) | JP2008519778A (es) |
| AR (1) | AR054988A1 (es) |
| AU (1) | AU2005304066B2 (es) |
| CA (1) | CA2586929A1 (es) |
| DE (1) | DE102004054216A1 (es) |
| WO (1) | WO2006050779A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2150544B1 (en) * | 2007-03-19 | 2016-01-13 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN112225748B (zh) * | 2020-10-20 | 2021-11-30 | 四川大学华西医院 | 一种具有flt3激酶抑制活性的小分子化合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002044156A2 (en) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
-
2004
- 2004-11-10 DE DE102004054216A patent/DE102004054216A1/de not_active Withdrawn
-
2005
- 2005-10-12 JP JP2007540514A patent/JP2008519778A/ja active Pending
- 2005-10-12 EP EP05791308A patent/EP1809629B1/de not_active Not-in-force
- 2005-10-12 CA CA002586929A patent/CA2586929A1/en not_active Abandoned
- 2005-10-12 US US11/667,132 patent/US7846927B2/en not_active Expired - Fee Related
- 2005-10-12 WO PCT/EP2005/010957 patent/WO2006050779A1/de active Application Filing
- 2005-10-12 AU AU2005304066A patent/AU2005304066B2/en not_active Ceased
- 2005-11-09 AR ARP050104688A patent/AR054988A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005304066A1 (en) | 2006-05-18 |
| DE102004054216A1 (de) | 2006-05-11 |
| CA2586929A1 (en) | 2006-05-18 |
| EP1809629B1 (de) | 2012-06-13 |
| WO2006050779A1 (de) | 2006-05-18 |
| US7846927B2 (en) | 2010-12-07 |
| US20070293488A1 (en) | 2007-12-20 |
| EP1809629A1 (de) | 2007-07-25 |
| JP2008519778A (ja) | 2008-06-12 |
| AU2005304066B2 (en) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054988A1 (es) | 4-amino-piridopirimidinonas sustituidas, un procedimiento para preparar los compuestos y medicamento en base a aquellos | |
| AR051623A1 (es) | Derivados de piridopirimidinona | |
| AR053569A1 (es) | Derivados de pirazol | |
| ES2524966T3 (es) | Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer | |
| AR066543A1 (es) | Derivados de piridazinona | |
| BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR046929A1 (es) | Piridopirimidinonas | |
| AR061574A1 (es) | Derivados de 3- amino- imidazo [1,2-a] piridina | |
| AR058205A1 (es) | 5-fenil-3,6-dihidro-2-oxo-6h-[1,3,4] tiadiazinas sustituidas | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
| AR096235A1 (es) | Arilquinazolinas | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
| AR057899A1 (es) | Derivados de 3,6-dihidro-2-oxo-6h-[1,3,4]tiadiazina, metodo de preparacion, composiciones farmaceuticas que los contienen y usos en la terapia contra el cancer | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| AR056310A1 (es) | Derivados de purina, procedimiento de obtencion, composiciones farmaceuticas y usos | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| AR078313A1 (es) | Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR072860A1 (es) | Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina | |
| ECSP088805A (es) | 2-(piridin-2-il)-pirimidinas como fungicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |